Development of mRNA Therapeutics for the Prevention & Treatment of Respiratory Diseases
- Clinical update on ETH47 – a first-in-class mRNA-based nasal spray treatment for uncontrolled asthma
- ETH47 encodes interferon lambda (IFNλ), aiming to boost innate immune defense in the airways and address viral triggers of asthma exacerbations
- Development of spray-dried mRNA for formulation for respiratory tract delivery
- Next generation mucosal mRNA vaccines for transmission blocking